“Forgiving” a Missed Daily Dose

Osterberg L , Blaschke T . Adherence to medication. N Engl J Med, 2005; 353,5:487–497.

Macha S , Yong CL , Darrington T et al. In vitro-in vivo correlation for nevirapine extended release tablets. Biopharm Drug Dispos, 2009; 30,9:542–550.

Gathe J , Knecht G , Orrell C et al. 48 Week Efficacy Pharmacokinetics, Safety of Once a Day 400 mg Nevirapine Extended Release Formulation for Treatment of Antiretroviral Naïve HIV-1 Infected Patients [VERxVE] Presented at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 12–15, 2010, Boston, MA, 2010Abstract H-1808.

Macha S , Yong CL , MacGregor TR et al. Assessment of nevirapine bioavailability from targeted sites in the human gastrointestinal tract. J Clin Pharmacol, 2009; 49,12:1417–1425.

Apisarnthanarak A , Mundy LM . Long-term outcomes of HIV-infected patients with <95% rates of adherence to nonnucleoside reverse-transcriptase inhibitors. Clin Infect Dis, 2010; 51,1:115–117.

Kappelhoff BS , Huitema AD , van Leth F et al. Pharmacokinetics of nevirapine: Once-daily versus twice-daily dosing in the 2NN study. HIV Clin Trials, 2005; 6,5:254–261.